Magtein® (Magnesium L-Threonate)

Evidence Level
Strong
2 Clinical Trials
4 Documented Benefits
4/5 Evidence Score

Magtein® (ThreoTech / AIDP) is a patented form of magnesium L-threonate — the only magnesium compound clinically demonstrated to cross the blood-brain barrier and significantly increase brain magnesium concentrations. While other magnesium forms (glycinate, citrate, oxide) improve systemic magnesium status, only the L-threonate ligand in Magtein® acts via glucose transporters to selectively elevate magnesium in the cerebrospinal fluid and brain tissue. Multiple double-blind RCTs confirm Magtein® improves working memory, cognitive performance, cognitive age, reaction time, and sleep quality at 2g/day.

Studied Dose 2g/day Magtein® (145 mg elemental magnesium); taken as 1g morning + 1g evening; 6-week minimum for cognitive benefits; most RCTs at 2g/day; EU Novel Food approved; NSF certified
Active Compound Magnesium L-threonate — Magtein® by ThreoTech Inc., distributed by AIDP; 2g Magtein® delivers 145 mg elemental magnesium; patented formula with EU Novel Food approval 2024

Brain magnesium elevation — only form crossing the blood-brain barrier

Preclinical research and human studies confirm Magtein® is the only magnesium form that meaningfully increases brain magnesium concentrations. The L-threonate ligand is transported via GLUT glucose transporters across the blood-brain barrier, enabling direct neuronal magnesium supplementation that other forms cannot achieve. Brain magnesium is essential for synaptic plasticity, NMDA receptor function, and the neuronal signaling underlying memory and cognition.

Cognitive performance and working memory improvement

Multiple RCTs confirm Magtein® (2g/day × 6 weeks) significantly improves overall cognitive performance, working memory, reaction time, hand-eye coordination, and reduces cognitive brain age. The 2025 Frontiers in Nutrition RCT in 100 adults (aged 18–45) confirmed these benefits in younger adults — extending earlier evidence from older adult cognitive decline studies that showed a ~9-year reversal of cognitive age with Magtein® supplementation.

Sleep quality and parasympathetic nervous system support

A 2025 double-blind RCT in adults with self-reported poor sleep confirmed Magtein® supplementation significantly improved subjective sleep quality (PROMIS Sleep questionnaire), reduced resting heart rate, and increased heart rate variability during sleep — indicating improved parasympathetic activity. Separately, a 21-day RCT in 80 middle-aged adults with sleep problems confirmed improved sleep quality and daytime functioning with 1g/day magnesium L-threonate.

Stress and cognitive aging support

Magnesium deficiency is prevalent in modern diets and directly impairs cortisol regulation, GABA signaling, and stress resilience. Magtein®'s brain-targeted magnesium delivery specifically addresses the neurological component of magnesium deficiency — supporting GABAergic inhibitory tone that reduces anxiety and cortisol-driven cognitive impairment, and maintaining NMDA receptor function essential for healthy cognitive aging.

1

GLUT transporter-mediated brain magnesium elevation and synaptic plasticity

The L-threonate component of Magtein® binds glucose transporters (GLUT1, GLUT3) on the blood-brain barrier endothelium, enabling active transport of the magnesium-threonate complex into cerebrospinal fluid — a transport pathway unavailable to other magnesium salts that require passive diffusion. Once in the brain, elevated magnesium activates synaptic plasticity mechanisms: reducing NMDA receptor over-activation (which drives neuronal fatigue and cognitive decline), supporting long-term potentiation (memory consolidation), and enhancing GABAergic inhibitory tone for stress regulation and sleep quality.

1
Magtein® Cognitive Performance and Sleep — Double-Blind RCT (2025)
PubMed

Randomized, double-blind, placebo-controlled parallel-arm trial of Magtein® (2g/day) in 100 adults aged 18–45 with self-reported poor sleep. 6-week study. Published in Frontiers in Nutrition 2025.

100 healthy adults aged 18–45 with dissatisfied sleep. 6-week parallel-arm RCT.

Magtein® significantly improved overall cognitive performance, working memory, reaction time, hand-eye coordination, and cognitive age vs. placebo. Resting heart rate reduced; HRV during sleep increased (improved parasympathetic activity). Subjective sleep quality improved. First study confirming cognitive benefits in younger adult population.

2
Magtein® Cognitive Age Reversal in Mild Cognitive Impairment — RCT
PubMed

12-week randomized controlled trial of Magtein® in older adults with mild cognitive impairment.

Older adults with mild cognitive impairment. 12-week RCT.

Magtein® supplementation significantly improved total cognitive score, equivalent to approximately 9-year cognitive improvement vs. placebo — suggesting meaningful reversal of age-related cognitive decline. Supports Magtein® as a clinically relevant intervention for healthy cognitive aging.

Common Potential side effects

Generally well tolerated at 2g/day clinical dose
Mild GI effects possible — take with food
Drowsiness in some users — evening dose 1–2 hours before bed is standard
Not a high-dose elemental magnesium supplement — 145 mg/day is below laxative threshold

Important Drug interactions

Antibiotics (tetracyclines, fluoroquinolones) — magnesium may reduce absorption; space by 2 hours
Bisphosphonates — take separately; magnesium impairs bone drug absorption
Diabetes medications — threonate (glucose transporter) mechanism; no established glucose interaction at clinical doses